Stock of the Day

Horizon Therapeutics Public (HZNP)

$116.30

$0.00 (0.0%)

Market Cap: $26.63B

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.

Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Horizon Therapeutics Public Bull Case

Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited:

• The current stock price is around $80, reflecting a strong market position and investor interest in the company's innovative therapies.
• Horizon Therapeutics Public Limited has a diverse portfolio of 12 medicines targeting rare diseases and severe inflammatory conditions, which can lead to stable revenue streams.
• The company has established collaboration agreements with several biotech firms, enhancing its research capabilities and potential for future product development.
• Recent advancements in their flagship products, such as TEPEZZA for thyroid eye disease, have shown promising results, potentially increasing market share and sales.
• As a biotechnology company focused on critical health needs, Horizon Therapeutics Public Limited is well-positioned to benefit from increasing demand for specialized treatments in the pharmaceutical industry.

Horizon Therapeutics Public Bear Case

Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons:

• Market competition in the biotechnology sector is intense, with many companies developing similar therapies, which could impact Horizon's market share.
• Regulatory challenges can arise, potentially delaying product approvals and affecting revenue projections.
• Dependence on a limited number of key products for revenue can pose risks if those products face market or regulatory issues.
• Recent fluctuations in stock price may indicate volatility, which can be a concern for risk-averse investors.
• Investors should consider the potential for high research and development costs, which can impact profitability in the short term.